Methotrexate increases valproic acid‐induced developmental toxicity, in particular neural tube defects in mice
- 1 January 1992
- journal article
- Published by Wiley in Teratogenesis, Carcinogenesis, and Mutagenesis
- Vol. 12 (5), 203-210
- https://doi.org/10.1002/tcm.1770120503
Abstract
The hypothesis that valproic acid‐induced dysmorphogenesis may be due to an interference of this drug with folate metabolic pathways was further investigated by a study of a possible interaction of valproic acid (VPA) and the established folate antagonist methotrexate (MTX). The dihydrofolate reductase inhibitor MTX (1.25 and 2.5 mg/kg, i. p.) was injected 15 min prior to VPA (300 and 400 mg/kg, s. c.) in day 8 pregnant NMRI mice. Fetuses were examined for exencephaly, resorption, and fetal weight retardation on day 18 of gestation. MTX produced no exencephaly or reduction in fetal weight, and the 2.5‐mg/kg dose caused 56% resorption. Higher doses (5–20 mg/kg) produced embryolethality and fetal weight retardation, but no exencephaly. VPA (300 and 400 mg/kg) administration resulted in 3.4% and 12.6% exencephaly and 9% and 19% resorptions, respectively. Coadministration of MTX with VPA significantly increased VPA‐induced resorption and exencephaly rates as well as fetal weight retardation. Exencephaly induced by VPA 400 mg/kg was increased to 29.5% and 24.1% (P < 0.01 and P < 0.05) when given with 1.25 and 2.5 mg/kg MTX, respectively. MTX (2.5 mg/kg i.p.) did not alter transplacental VPA (400 mg/kg, s.c.) pharmacokinetics. These results support the view that VPA‐induced teratogenesis may be mediated by interaction with folate metabolism.Keywords
This publication has 22 references indexed in Scilit:
- The enantioselective teratogenicity of 2-n-propyl-4-pentynoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokineticsToxicology Letters, 1992
- Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in miceFundamental and Applied Toxicology, 1992
- Valproic Acid‐Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible MechanismsBasic & Clinical Pharmacology & Toxicology, 1991
- Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouseLife Sciences, 1987
- Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acidThe Journal of Pediatrics, 1986
- Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs conventional injection regimen in the mouseToxicology and Applied Pharmacology, 1985
- EMBRYOTOXICITY TESTING OF VALPROIC ACIDThe Lancet, 1983
- A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrationsLife Sciences, 1981
- Teratogenicity of valproic acid: In vivo and in vitro investigationsTeratogenesis, Carcinogenesis, and Mutagenesis, 1981
- Teratogenicity of methotrexate in miceTeratology, 1974